Never mind the Cash ISA. I think these stock market stalwarts will help you beat a recession

Paul Summers picks out three defensive stocks that should hold their own in the event of a Brexit-linked recession.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Having some cash in the bank is never a bad idea and with more than a few analysts predicting that the UK could slip into recession following Brexit, it’s particularly prudent at the current time.  

Many of us will be using a Cash ISA for this purpose. The fact that these accounts pay interest way below inflation, however, means it’s vital not to leave any surplus funds in there — that is, anything beyond roughly six months of living expenses.

As such, here are three resilient companies I’d consider buying for my portfolio with what’s left over. 

Recession-proof

People will always need medicine, regardless of what the economy is doing. As such, my first port of call is the pharmaceutical industry and, more specifically, GlaxoSmithKline (LSE: GSK). 

Despite the fact that it’s not been increased since 2014, one of the biggest attractions to Glaxo, aside from its defensive qualities, is its dividend. The 80p per share total payout for the current financial year means a yield of almost 4.8%. Perhaps most importantly, the extent to which this cash return is covered by profits is starting to look more stable after a rocky few years. 

Unsurprisingly given the Brexit stand-off, Glaxo’s shares have been steadily growing in popularity, rising 11% since the beginning of 2019. Assuming analysts are correct in their predictions, the shares currently change hands for just over 14 times earnings — far below FTSE 100 peer Astrazeneca’s frothy-looking P/E of 24. 

Another stock that should hold its own in the aftermath of Brexit, if it happens at all, is waste management and recycling firm Biffa (LSE: BIFF).

Last week’s trading update was as no-nonsense as you can get with the company stating that trading over H1 had been in line with management expectations with no change to the outlook for the full year. 

Of course, a business like this will never generate the same level of excitement as your average tech company. On a little less than 10 times earnings, however, I’m tempted to say that Biffa looks cheap.

At its current price, the forecast dividend yield sits close to 3.6% and is easily covered by earnings. There’s quite a bit of debt on the balance sheet (something I usually steer clear of), but the predictability of its line of work arguably makes this less of a red flag.

My last pick is a retailer. That might sound strange considering that consumer confidence is usually battered during economic wobbles, but stick with me.

Here I’m talking about discount retailers — the sort that offer people the most bang for their buck. FTSE 250 member B&M European Value (LSE: BME) is the standout candidate here, especially when recent trading is considered.

In late July, the company stated that it had made a “solid start” to FY20 with group revenue climbing 21.4% over Q1 (31 March-29 June). In sharp contrast to high street peers, 12 new stores were opened over the period with lots more planned over the entire year.

This optimistic outlook goes some way to explaining why B&M’s shares trade on almost 18 times forecast earnings. The 2.4% yield is also the lowest of the three in focus today (although it’s been hiked by double-digits in three of the last four years). With signs that consumers are continuing to tighten the purse strings, however, I think this is still a reasonable price to pay. 

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK owns shares of B&M European Value. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

ChatGPT thinks these are the 5 best FTSE stocks to consider buying for 2026!

Can the AI bot come up trumps when asked to select the best FTSE stocks to buy as we enter…

Read more »

Investing For Beginners

How much do you need in an ISA to make the average UK salary in passive income?

Jon Smith runs through how an ISA can help to yield substantial income for a patient long-term investor, and includes…

Read more »

Investing Articles

3 FTSE 250 shares to consider for income, growth, and value in 2026!

As the dawn of a new year in the stock market approaches, our writer eyes a trio of FTSE 250…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Want to be a hit in the stock market? Here are 3 things super-successful investors do

Dreaming of strong performance when investing in the stock market? Christopher Ruane shares a trio of approaches used by some…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

The BP share price has been on a roller coaster, but where will it go next?

Analysts remain upbeat about 2026 prospects for the BP share price, even as an oil glut threatens and the price…

Read more »

Investing Articles

Prediction: move over Rolls-Royce, the BAE share price could climb another 45% in 2026

The BAE Systems share price has had a cracking run in 2025, but might the optimism be starting to slip…

Read more »

Tesla car at super charger station
Investing Articles

Will 2026 be make-or-break for the Tesla share price?

So what about the Tesla share price: does it indicate a long-term must-buy tech marvel, or a money pit for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Apple CEO Tim Cook just put $3m into this S&P 500 stock! Time to buy?

One household-name S&P 500 stock has crashed 65% inside five years. Yet Apple's billionaire CEO sees value and has been…

Read more »